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In Brief
The Polycomb group protein CBX7
functions to regulate gene transcriptional
repression via its chromodomain binding
tomethylated lysine 27 of histone H3. Ren
et al. report a small molecule that inhibits
the CBX7 chromodomain and
derepresses target gene p16/CDKN2A in
PC3 prostate cancer cells.
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Chromobox homolog 7 (CBX7) plays an important
role in gene transcription in a wide array of cellular
processes, ranging from stem cell self-renewal and
differentiation to tumor progression. CBX7 functions
through its N-terminal chromodomain (ChD), which
recognizes trimethylated lysine 27 of histone 3
(H3K27me3), a conserved epigenetic mark that sig-
nifies gene transcriptional repression. In this study,
we report the discovery of small molecules that
inhibit CBX7ChD binding to H3K27me3. Our crystal
structures reveal the binding modes of these
molecules that compete against H3K27me3 binding
through interactions with key residues in the
methyl-lysine binding pocket of CBX7ChD. We
further show that a lead compound, MS37452, dere-
presses transcription of Polycomb repressive com-
plex target gene p16/CDKN2A by displacing CBX7
binding to the INK4A/ARF locus in prostate cancer
cells. These small molecules have the potential to
be developed into high-potency chemical modula-
tors that target CBX7 functions in gene transcription
in different disease pathways.
INTRODUCTION
Polycomb group (PcG) proteins were first identified in
Drosophila as silencers of transcription of the bithorax gene
complex (BX-C), a group of homeotic (Hox) genes responsible
for controlling segmentation (Lewis, 1978). PcG proteins also
play a fundamental role in multicellular organism development
and cancer progression (Sauvageau and Sauvageau, 2010).
PcG proteins function in two main complexes: Polycomb
repressive complex 2 (PRC2) deposits a repressive histone
H3 lysine 27 methylation (H3K27me3) mark by EZH2; Polycomb
repressive complex 1 (PRC1) recognizes H3K27me3 through
chromodomain (ChD)-containing Chromobox homolog (CBX)
proteins and ubiquitinates H2AK119 by RING1A/B. However,
the precise mechanism by which PcG proteins are recruited
to repress gene transcription is not fully understood (Simon
and Kingston, 2009).Chemistry & Biology 22, 161A key PRC1 protein, CBX7 was first identified in functional
cDNA screening, designed to extend the life-span of normal hu-
man prostate epithelial cells by repressing the Ink4a/Arf locus
(Gil et al., 2004). This locus encodes key regulators of both reti-
noblastoma tumor suppressor (Rb) and p53 (Sherr, 2001, 2006);
p14Arf/p53- and p16Ink4a/Rb-dependent impairment of cell
growth upon CBX7 knockdown highlights CBX7’s role in tumor-
igenesis (Bernard et al., 2005). CBX7 is also important in stem
cell self-renewal and differentiation (Klauke et al., 2013; Morey
et al., 2012).
Similar to other CBX proteins, CBX7 is characteristic of an
N-terminal ChD responsible for recognition of the repressive
mark, H3K27me3. The methyl-lysine binding pocket (also called
the ‘‘aromatic cavity’’) is formed by three aromatic residues
(Phe11, Trp32, and Trp35 in CBX7), which are highly conserved
among all ChD proteins (Bernstein et al., 2006; Kaustov et al.,
2011). Mutations of these residues cause CBX7 dissociation
from chromatin and alter the life-span of prostate epithelial cells,
underscoring the importance of ChD/H3K27me3 binding for
CBX7 activity (Gil et al., 2004; Morey et al., 2012; Yap et al.,
2010). Thus, we postulated that small-molecule disruption of
CBX7ChD binding to H3K27me3would inhibit the transcriptional
activity of CBX7 and result in derepression of its target genes.
Such small molecules could be used to fine-tune a balance be-
tween stem cell self-renewal and differentiation, and could also
be developed into potential new therapeutics for cancer treat-
ment. Despite the functional importance of CBX7 in gene regula-
tion, only recently have macrocyclic calixarenes (Tabet et al.,
2013) and peptidomimetics (Simhadri et al., 2014) been shown
asCBX7ChD antagonists, but no small-molecule chemical inhib-
itors have been reported for CBX7ChD or other CBXChDs. Here,
we report the discovery and characterization of small-molecule
chemical modulators of the CBX7ChD, and demonstrate that a
lead compound, MS37452, induces transcriptional derepression
of p16/CDKN2A by disrupting CBX7ChD binding to H3K27me3
at the INK4A/ARF locus in PC3 prostate cancer cells.
RESULTS AND DISCUSSION
While an H3K27me3 peptide is a well-established biological
ligand for CBX7ChD (Bernstein et al., 2006; Yap et al., 2010),
its binding affinity is modest (Kd = 27.7 mM) (Figure 1A; Table
S1), making it less ideal as a probe for high-throughput chemical
screening. To address this issue, we evaluated another trimethy-
lated lysine peptide of SETDB1 at K1170 (SETDB1K1170me3)–168, February 19, 2015 ª2015 Elsevier Ltd All rights reserved 161
Figure 1. Structural Analysis of H3K27me3 and SETDB1 Recognition by CBX7ChD
(A) Measurement of CBX7ChD binding to lysine-methylated H3 and SETDB1 peptides using a fluorescence anisotropy assay. Results were plotted from at least
two independent experiments and error bars denote the SEM.
(legend continued on next page)
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reported to bind to CBX7ChD with higher affinity (Kaustov et al.,
2011). Despite similar core sequences of ARKme3S and
ALKme3S for H3K27me3 and SETDB1, respectively, the
SETDB1 peptide binds to CBX7ChD with much higher affinity
(Kd = 1.3 mM) (Figure 1A). The enhanced binding of the SETDB1
peptide is supported by 2D 1H-15N-heteronuclear single quan-
tum coherence (HSQC) nuclear magnetic resonance (NMR)
spectra (Figure 1B), and also confirmed by a fluorescence anisot-
ropy binding study (see Figure S2J), thus making SETDB1-
1170me3 an attractive probe for high-throughput screening.
To determine the molecular basis of CBX7ChD binding to
these lysine-methylated peptides, we solved 1.45 A˚ and 1.60 A˚
resolution crystal structures of CBX7ChD bound to an
H3K27me3 or SETDB1-K1170me3 peptide, respectively (Fig-
ures 1C and 1D; Table S2). In the methyl-lysine binding aromatic
cavity, the indole of Trp35 recognizes three methyl groups of
Kme3, while Phe11 and Trp32 form the base to interact with
the acyl side chain of the methylated lysine (Figure 1E; Figures
S1A–S1C). The H3K27me3 peptide binds across the protein
with residues Ala24-Ala25-Arg26-K27me3 forming a two-strand
antiparallel b sheet with the N-terminal Val10-Ala12 of the protein
(Figure 1F). The CBX7ChD has an expanded interface for the
SETDB1 peptide with a longer N-terminal b strand composed
of Gly7-Ala12 (Figures 1D and 1G). This antiparallel b sheet is en-
forced by an extended network of intermolecular hydrogen-bond
interactions involving protein residues Gly7 and Asp50, as well
as hydrophobic interactions with Leu53 that are absent in the
H3K27me3-bound structure (Figure 1H). These findings explain
the molecular basis for the enhanced affinity of CBX7ChD for
SETDB1-K1170me3 over H3K27me3.
We next conducted high-throughput screening of a library of
2,560 Food and Drug Administration (FDA)-approved drug mol-
ecules and an L1 library of 100,160 compounds selected from
commercial sources to identify inhibitors for the CBX7ChD using
a fluorescence anisotropy binding assay with a fluorescein iso-
thiocyanate (FITC)-labeled SETDB1-K1170me3 peptide as an
assay probe (see Supplemental Information). A B score <6
was set as the criterion to select initial hits, of which 16 were
identified from the FDA library and 40 from the L1 library (Fig-
ure 2A). Of these initial hits, five hits from the FDA and one hit
from the L1 library were confirmed as binders of the CBX7ChD
by using 2D 1H-15N HSQC spectra (Figures S2A–S2H and S3)
and the fluorescence anisotropy binding assay (Figure 2B).
MS37452 was the only chemical hit confirmed from the L1
library with binding affinity (Kd) of 28.90 ± 2.71 mM to the
CBX7ChD, as determined by NMR titration (Figure S2I).
MS37452 disrupts CBX7-H3K27me3 or H3K9me3 binding with
Ki of 43.0 and 55.3 mM, respectively, as shown in a fluorescence
anisotropy binding assay (Figure S2J).
We then solved a 2.14 A˚ resolution crystal structure of the
CBX7ChD-MS37452 complex (Table S2). Strikingly, MS37452(B) 2D 1H-15N-HSQC spectra of 15N-CBX7ChD in free (black) or in the presence
(C) Crystal structure of CBX7ChD bound to an H3K27me3 peptide. CBX7ChD is
(D) Crystal structure of CBX7ChD bound to the SETDB1-K1170me3 peptide.
(E) Structural overlay of CBX7ChD bound to the H3K27me3 or SETDB1-K1170m
(F and G) Analysis of CBX7ChD bound to H3K27me3 or SETDB1-K1170me3, resp
are shown.
(H) Comparison of SETDB1 and H3K27me3 binding to CBX7ChD. See also Figu
Chemistry & Biology 22, 161adapts two rotamer conformations. The dimethoxylbenzene
and piperazine moieties of MS37452 are bound in the same
orientation interacting with Phe11, Trp32, and Trp35 in the aro-
matic cavity, or sandwiched between Phe11 and Trp32, respec-
tively, whereas the methylbenzene moiety adopts a cis or trans
conformation with respect to the dimethoxylbenzene, hinged at
the carbonyl that connects the methylbenzene to the piperazine
ring (Figure 2C). Notably, in the trans conformation, the methyl-
benzene is positioned in the ChD similarly to H3K27me3 and
SETDB1-K1170me3, forming interactions with His47, Val13,
and Glu43 (Figures 2D–2G). On the other hand, in the cis confor-
mation, the methylbenzene swings upward into the protein
structure, disrupting the N-terminal b strand and compromising
the stability of the complex (Figure 2D, left). The trans conforma-
tion is secured by water-mediated hydrogen bonding of the
ligand’s two carbonyl groups with protein residues His5 (from
His-tag) and Tyr39 (Figure 2D, right). In either conformation,
Trp35 is pushed outward to accommodate the dimethoxylben-
zenemoiety within the aromatic cavity (Figures 2E and 2G). Point
mutations of Phe11, Trp35, or Tyr39 to Ala almost completely
abolished CBX7ChD-MS37452 binding (Figure S2I). These re-
sults confirmed that the aromatic cage residues and Tyr39 are
critical to the CBX7ChD-MS37452 interaction.
We next examined the selectivity of MS37452 for different
CBXChDs. MS37452 binds to a subgroup of CBXChDs,
including those of CBX2, CBX4, CBX6, and CBX8, but shows
almost no binding to ChDs of CBX1, CBX3, and CBX5 that are
also known as heterochromatin 1 (HP1) b, g, and a (Figures
S1B and S2). As determined by HSQC titration, MS37452 has
approximately a 3-fold and at least 10-fold weaker affinity for
CBX4 or CBX2/CBX6/CBX8 than for CBX7, respectively (Fig-
ure S2I). The difference in MS37452 affinity between these two
subgroups is most likely due to Trp35, which is replaced by a
Phe in the HP1 ChDs (see Figure S1C). Phe has a smaller side
chain than Trp, and is not sufficient to accommodate two me-
thoxyls when the aromatic cage residues adopt an extended
conformation upon MS37452 binding (Figure S1D). The differ-
ence between CBX7 and CBX2/CBX4/CBX6/CBX8 is possibly
due to the collective role of Tyr39, Val13, and His47 (see Fig-
ure S1C). Specifically, Tyr39 is substituted to Asp in CBX2/
CBX4/CBX6/CBX8, which results in loss of aromatic stacking
interaction with the dimethoxylbenzene ring of MS37452. Val13
in CBX7 andCBX4 corresponds to an Ala in CBX2/6/8, which de-
creases hydrophobic interactions with themethylbenzene ring of
MS37452. The presence of Val13 in both CBX4 and CBX7 ex-
plains their comparable binding affinity to MS37452. Finally,
the presence of Asn in CBX2/CBX4/CBX6/CBX8 instead of
His47 in CBX7 contributes to loss of imidazole ring interactions
with the methylbenzene ring of MS37452.
We also collected structure-activity relationship data for
MS37452 with chemical analogs either available in the L1 libraryof H3K27me3 (red, left panel), or SETDB1-1170me3 peptide (red, right panel).
depicted in green while H3K27me3 is depicted in salmon.
e3 peptide.
ectively. Only residues involved in hydrogen bond or hydrophobic interactions
re S1, and Tables S1 and S2.
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Figure 2. Discovery of Small-Molecule Inhibitors of CBX7ChD
(A) Hits identified from HTS and confirmed by 2D 1H-15N-HSQC spectra. Compounds from L1 (100,000 compounds) and FDA (2,600 compounds) libraries were
plotted according to B score. All hits with B score <6 were further tested by 2D 1H-15N-HSQC spectra, of which the confirmed hits are highlighted with colored
dots.
(B) Measurement of CBX7ChD binding to small molecules in a fluorescence polarization assay using FITC-labeled SETDB1-K1170me3 peptide as an assay
probe. IC50 was determined using GraphPad Prism. Results were plotted from at least two independent experiments and error bars denote the SEM.
(C) Superimposition of crystal structures of CBX7ChD in complex with MS37452 in cis or trans conformation.
(D) Analysis of CBX7ChD binding to cis-MS37452 or trans-MS34752. Only residues involved in hydrophobic or hydrogen bond interactions are shown.
(E) Structural comparison of the CBX7ChD bound to MS37452 or H3K27me3 peptide.
(F) Electrostatic potential surface representation of CBX7ChD bound to cis-MS37452 (left) or trans-MS37452 (right).
(G) Superimposition of the structures of CBX7ChD bound to H3K27me3 peptide or MS37452 illustrating conformational change of the Kme3 binding aromatic
cage. See also Figures S1 and S2, and Tables S2 and S3.or synthesized (see Supplemental Information and Table S3).
The analogs that contain Cl, Br, or no methyl group substitutions
on the methylbenzene ring bind to the CBX7ChD with reduced
affinity in the range of a B score less than 3 but greater164 Chemistry & Biology 22, 161–168, February 19, 2015 ª2015 Elsethan 6. Analogs lacking one of the two methoxyls (or switching
their positions) almost abolishes binding, indicating that the size
and position of the two methoxyls are critical for maintaining
MS37452’s interaction with Trp35 of the protein. However, wevier Ltd All rights reserved
did not find a compound with affinity greater than MS37452.
Collectively, these results indicate that both the dimethoxylben-
zene and methylbenzene moieties contribute to overall binding.
The former is secured by its interaction with the aromatic cavity
residues and Tyr39, whereas the latter is bound in a conforma-
tion similar to the methylated lysine, sandwiched between b1
and a1.
Among the hits identified and confirmed from the FDA library
(Figure 2A; Figure S3) are sennoside A, suramin, aurin tricarbox-
ylic acid, trypan blue, and Evans blue. They bind to theCBX7ChD
with affinities (IC50) of 33.3, 8.1, 5.5, 7.5, and 3.9 mM, respectively
(Figure 2B). Unlike MS37452, these compounds share common
features: relatively large in molecular weight, symmetric, and
containing polyhydroxyl groups. Their binding to CBX7ChD
also induces severe line broadening in NMRHSQC spectra, indi-
cating ligand binding-induced conformational exchange of the
protein (Figure S3). We extended our analysis on suramin, which
is colorless, water soluble, and shown to induce protein dimer-
ization (Lima et al., 2009).
We solved a 1.63 A˚ resolution crystal structure of the
CBX7ChD-suramin complex, which strikingly reveals two sura-
min molecules bound to two CBX7ChD molecules in a unit cell
(Figure 3A; Table S2). One suramin molecule lies along the
cleft/tunnel between the two b sheets of each CBX7ChD and
glues the two domains together, and is thus referred to as ‘‘sur-
amin glue’’ (Figures 3A and 3B, yellow). The other suramin re-
sides along the plane created by the two b sheets, orthogonal
to suramin glue (Figures 3A and 3B, salmon), and locks the
two CBX7ChD molecules in the region of Lys19 to Gly24, where
the b sheets start to turn, and thus is named ‘‘suramin lock.’’ For
the tunnel where suramin glue lies, Trp32 and Trp35 from two
CBX7ChD molecules form the hydrophobic binding pocket. In
contrast, Phe11 either rotates (chain B) or points outside the
binding tunnel (chain A), so its aromatic ring does not contribute
to binding (Figures 3A–3D). A large number of direct or water-
mediated hydrogen bonds are established at an extensive inter-
face between suramin and CBX7ChD (Figure 3C). The urea and
four amide groups form hydrogen bonds on the bottom surface
of the binding tunnel. The sulfonate groups of the suramin glue
interact with a stretch of charged residues Arg20, Glu46, and
His47 to facilitate the binding via electrostatic interactions.
Suramin-lock only involves interactions with basic residues
from chain B, namely Lys19 and Lys23 (Figure 3C, right). In terms
of how these crystals are packed, CBX7ChD molecules lie in a
3D network weaved by suramin, and they form a compact 2:2
complex.
Aside from the methyl-lysine-based peptide inhibitors of the
CBXChDs, severalmethyl-lysine-bindingantagonists,particularly
against the MBT (malignant brain tumor) domain, have been
reported (James et al., 2013). MBTs have a narrow methyl-lysine
binding pocket and bind preferentially to H3K27me1 or me2,
instead of me3 (James et al., 2013). Notably, the aromatic cage
of L3MBTL3 comprises four residues, Phe387, Phe405, Trp408,
and Tyr412, which correspond to Phe11, Trp32, Trp35, and
Tyr39 of CBX7, respectively (Figure S1D). L3MBTL3 also contains
a critical Asp381, which together with the aromatic cage residues
creates a full pocket to accommodate the amine moiety of
UNC1215, a potentMBT inhibitor (James et al., 2013). In contrast,
aromatic cage residues and Tyr39 of CBX7ChD provide a half-Chemistry & Biology 22, 161closed pocket for MS37452 binding. Even considering the fact
that other residues contribute to MS37452 binding, the methyl-
lysine binding pocket of CBX7-MS37452 is still open. In other
words, the amine group of UNC1215 binds deep into the pocket
in L3MBTL3 while MS37452 lies along the surface groove of
CBX7ChD, thus explaining a major difference in affinity between
these two methyl-lysine reader domain inhibitors. In addition,
similar to the mode adopted by suramin in binding to CBX7ChD,
UNC1215 bridges different domains of L3MBT3 when bound to
the protein, thus resulting in a major increase in binding affinity
compared with UNC669 or similar compounds with different
linkers (James et al., 2013).
Given that suramin interacts with different proteins, including
thrombin and pyruvate kinase (Lima et al., 2009; Morgan et al.,
2011), we focused our study of small-molecule modulation of
CBX7ChD activity on transcriptional repression with MS37452.
Prior research showed that mutation or deletion of CBX7ChD re-
sults in a decrease in binding of CBX7 to the INK4A/ARF
(CDKN2A) locus at multiple sites (Figure 4A) (Bracken et al.,
2007). We indeed observed that human PC3 prostate cancer
cells treated with MS37452 (250 mM) for 2 hr showed reduced
CBX7 occupancy across the INK4A/ARF locus, as determined
by chromatin immunoprecipitation (ChIP) (Figure 4B). We further
examined INK4A/ARF transcript levels in PC3 cells using quan-
titative PCR upon dose- and time-dependent treatment of
MS37452 (Figures 4C and 4D). After treatment with MS37452
for 12 hr, transcription increased about 25% and 60% for
250 mM and 500 mM of MS37452, respectively, compared with
the DMSO control.
We further observed reduced occupancy of RING1B, and
H3K27me3 at the INK4A/ARF locus by MS37452, but much
less, if any, change of CBX4 or CBX8 (Figure 4B). MS37452
has much weaker affinity to CBX4ChD or ChX8ChD than to
CBX7ChD, consistent with weaker reduction of the former asso-
ciation with the INK4A/ARF locus. As a PRC1 component,
RING1B has been shown to interact with CBX7 and play a critical
role in CBX7 deposition at chromatin (Morey et al., 2013; Wang
et al., 2010). Therefore, a reduced RING1B association is consis-
tent with reduced CBX7 occupancy after the compound treat-
ment. The observed reduction of H3K27me3 matches the find-
ings of a previous study showing localized reduction in
H3K27me3 signal when CBX7 was silenced (Maertens et al.,
2009) without a change of global H3K27me3 level (Figure S4B).
Based on these ChIP and mRNA transcription results, we
concluded that MS37452 can disrupt CBX7 binding to the
INK4A/ARF locus, subsequently resulting in transcriptional dere-
pression of its target genes p14/ARF and p16/INK4a in PC3 cells.
SIGNIFICANCE
In this study, we discovered small molecules that inhibit
CBX7ChD binding to lysine-methylated peptides with affin-
ity better than its biological target, H3K27me3. One hit, sur-
amin, bridges twoCBX7ChDmolecules from two perpendic-
ular directions, and another hit, MS37452, directly competes
against H3K27me3 binding by occupying both the methyl-
lysine binding aromatic cage and an internal portion of the
protein. We further demonstrated that MS37452 blocks
CBX7 binding to its target INK4/ARF gene locus, and–168, February 19, 2015 ª2015 Elsevier Ltd All rights reserved 165
Figure 3. Structural Analysis of Suramin Binding to CBX7ChD
(A) Crystal structure of a CBX7ChD dimer bound to suramin glue (yellow) and suramin lock (salmon) molecules.
(B) Surface presentation of CBX7ChD bound to suramin.
(C) Detailed analysis of the interactions between CBX7ChD and suramin.
(D) Structural comparison of CBX7ChD bound to suramin or H3K27me3 peptide. Chain A and suramin glue from the CBX7ChD-suramin complex and chain AC
from the CBX7ChD-H3K27me3 complex were aligned.
See also Figure S3 and Table S2.
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Figure 4. Modulation of CBX7 Binding to INK4A/ARF Locus by MS37452
(A) Scheme illustrating the genomic organization of the INK4a/ARF/INK4b gene loci color-coded in pink, blue, and green for p16/INK4a, p14/ARF, and p15/INK4b,
respectively. Roman numerals and arrows (red) denote sites of quantitative ChIP and PCR primers, respectively, as previously reported (Bracken et al., 2007).
(B) MS37452 reduces CBX7 occupancy at different positions along the INK4a/ARF locus in PC3 cells after 2 hr treatment of MS37452 (250 mM). Plot represents
data from one independent experiment (as an example) and error bars denote the SD of technical repeat. Independent ChIP data are listed in Figure S4.
(C and D) MS37452 induces gene transcriptional derepression at the INK4a/ARF locus, in a concentration- and time-dependent manner, in PC3 cells. mRNA
levels of p14/ARF and p16/INK4a were tested using SYBR quantitative PCR after MS37452 treatment. Data were plotted from at least three independent ex-
periments, and error bars denote the SEM. *p < 0.05, **p < 0.01.
See also Figure S4 and Table S4.
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induces derepression of p14/ARF and p16/INK4a in human
PC3 cells. Collectively, our structure-guided discovery and
characterization of small molecules for the CBX7ChD
demonstrate the promise and feasibility of developing selec-
tive chemical inhibitors of this important epigenome reader
domain protein. Given the fundamental role of CBX7 in PRC-
directed transcriptional repression of the Ink4a/Arf locus in
biology and disease, such new inhibitors can potentially be
used to provide senescence control, cancer prevention,
and stem cell lineage specification.
EXPERIMENTAL PROCEDURES
Procedures for protein expression and purification, biochemical binding
assay, and high-throughput chemical screening, protein structural analysis us-
ing NMR and X-ray crystallography, and cellular analysis of effects of com-
pound treatment in gene transcription are reported in detail in Supplemental
Experimental Methods.
SUPPLEMENTAL INFORMATION
Supplemental Information includes detailed experimental methods, four fig-
ures and four tables and can be found with this article online at http://dx.doi.
org/10.1016/j.chembiol.2014.11.021.
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